Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line

Biomedicine and Pharmacotherapy

Volumn 75, Issue , 2015, Pages 40-50

  Ayub, Ayunadirah ^a   Yip, Wai Kien ^a   Seow, Heng Fong ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

IGF 1R; MEK; MTORC; PI3K; Synergism; Triple negative breast cancer

Indexed keywords

5 [2 (2,6 DIMETHYLMORPHOLINO) 4 MORPHOLINOPYRIDO[2,3 D]PYRIMIDIN 7 YL] 2 METHOXYBENZENEMETHANOL; BUPARLISIB; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NVP AEW 541; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S6 KINASE; SOMATOMEDIN C RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; IGF1R PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MULTIPROTEIN COMPLEX; PROTEIN KINASE INHIBITOR; SOMATOMEDIN RECEPTOR; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CELL CYCLE G0 PHASE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME FACTOR; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MAP KINASE KINASE KINASES; MULTIPROTEIN COMPLEXES; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTORS, SOMATOMEDIN; SIGNAL TRANSDUCTION; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84944089045     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.08.031     Document Type: Article

References (35)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. In.t J. Cancer 2008, 127(12):2893-2917.
2. Higgins M.J., Baselga J. Targeted therapies for breast cancer. J. Clin. Invest. 2011, 121(10):3797-3803.
3. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011, 121(7):2750-2767.
4. Irvin W.J., Carey L.A. What is triple-negative breast cancer?. Eur. J. Cancer 2008, 44(18):2799-2805.
5. Cleator S., Heller W., Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007, 8(3):235-244.
6. Garcia-Echeverria C., Pearson M.A., Marti A., Meyer T., Mestan J., Zimmermann J., et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004, 5(3):231-239.
7. Hoeflich K.P., O'Brien C., Boyd Z., Cavet G., Guerrero S., Jung K., et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin. Cancer Res. 2009, 15(14):4649-4664.
8. Jacot J.L., Sherris D. Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy. J. Ophthalmol. 2011, 2011:589813.
9. Toniolo P., Bruning P.F., Akhmedkhanov A., Bonfrer J.M., Koenig K.L., Lukanova A., et al. Serum insulin-like growth factor-I and breast cancer. Cancer 2000, 88(5):828-832.
10. Yap T.A., Garrett M.D., Walton M.I., Raynaud F., de Bono J.S., Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 2008, 8(4):393-412.
11. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater?. J. Natl. Cancer Inst. 2012, 104(13):975-981.
12. Sachdev D., Yee D. The IGF system and breast cancer. Endocr. Relat. Cancer 2001, 8(3):197-209.
13. Belfiore A., Frasca F. IGF and insulin receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia 2008, 13(4):381-406.
14. Sachdev D., Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol. Cancer Ther. 2007, 6(1):1-12.
15. Paul M.K., Mukhopadhyay A.K. Tyrosine kinase-role and significance in cancer. Int. J. Med. Sci. 2004, 1(2):101-115.
16. Hopfner M., Sutter A.P., Huether A., Baradari V., Scherubl H. Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. World J. Gastroenterol. 2006, 12(35):5635-5643.
17. Bendell J.C., Rodon J., Burris H.A., de Jonge M., Verweij J., Birle D., et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 2012, 30(3):282-290.
18. Markman B., Dienstmann R., Tabernero J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget 2010, 1(7):530-543.
19. Miller T.W., Balko J.M., Fox E.M., Ghazoui Z., Dunbier A., Anderson H., et al. ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 2011, 1(4):338-351.
20. Fan Q.W., Weiss W.A. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors. Methods Mol. Biol. 2012, 821:349-359.
21. Hou J.Y., Rodriguez-Gabin A., Samaweera L., Hazan R., Goldberg G.L., Horwitz S.B., et al. Exploiting MEK inhibitor-mediated activation of ERalpha for therapeutic intervention in ER-positive ovarian carcinoma. PLoS One 2013, 4103:e54103.
22. Legrier M.E., Yang C.P., Yan H.G., Lopez-Barcons L., Keller S.M., Perez-Soler R., et al. Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res. 2007, 67(23):11300-11308.
23. Zhang H., Berel D., Wang Y., Li P., Bhowmick N.A., Figlin R.A., et al. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLoS One 2013, 8(1):e54918.
24. Chou T.C. Theoretical basis experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58(3):621-681.
25. Scotlandi K., Manara M.C., Nicoletti G., Lollini P.L., Lukas S., Benini S., et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 2005, 65(9):3868-3876.
26. Coulter D.W., Blatt J., D'Ercole A.J., Moats-Staats B.M. IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth. Anticancer Res. 2008, 28(3A):1509-1516.
27. Moser C., Schachtschneider P., Lang S.A., Gaumann A., Mori A., Zimmermann J., et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur. J. Cancer 2008, 44(11):1577-1586.
28. Sachdev D., Li S.L., Hartell J.S., Fujita-Yamaguchi Y., Miller J.S., Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res. 2003, 63(3):627-635.
29. Molina-Arcas M., Hancock D.C., Sheridan C., Kumar M.S., Downward J. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI kinase in KRAS-mutant lung cancer. Cancer Discov. 2013, 3(5):548-563.
30. Rodrik-Outmezguine V.S., Chandarlapaty S., Pagano N.C., Poulikakos P.I., Scaltriti M., Moskatel E., et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011, 1(3):248-259.
31. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118(9):3065-3074.
32. Mirzoeva O.K., Das D., Heiser L.M., Bhattacharya S., Siwak D., Gendelman R., et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009, 69(2):565-572.
33. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121(2):179-193.
34. Lasithiotakis K.G., Sinnberg T.W., Schittek B., Flaherty K.T., Kulms D., Maczey E., et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J. Invest. Dermatol. 2008, 128(8):2013-2023.
35. Rixe O., Fojo T. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?. Clin. Cancer Res. 2007, 13(24):7280-7287.